












Procedure file

Basic information		
DEC - Discharge procedure	2020/2153(DEC)	Procedure completed
2019 discharge: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)		
Subject 8.70.03.09 2019 discharge		

Key players			
European Parliament	Committee responsible	Rapporteur	Appointed
	 Budgetary Control	 CZARNECKI Ryszard	08/09/2020
		Shadow rapporteur	
		 ZDECHOVSKÝ Tomáš	
		 RÓNAI Sándor	
		 STRUGARIU Ramona	
		 EICKHOUT Bas	
		 OMARJEE Younous	
	Committee for opinion	Rapporteur for opinion	Appointed
	 Environment, Public Health and Food Safety	The committee decided not to give an opinion.	
	 Civil Liberties, Justice and Home Affairs		01/10/2020
		 CHINNICI Caterina	
European Commission	Commission DG Budget	Commissioner HAHN Johannes	

Key events			
29/06/2020	Non-legislative basic document published	COM(2020)0288	
15/09/2020	Committee referral announced in Parliament		
22/03/2021	Vote in committee		
30/03/2021	Committee report tabled for plenary	A9-0087/2021	
27/04/2021	Debate in Parliament		
28/04/2021	Decision by Parliament	T9-0177/2021	Summary

Technical information	
Procedure reference	2020/2153(DEC)
Procedure type	DEC - Discharge procedure
Other legal basis	Rules of Procedure EP 159
Stage reached in procedure	Procedure completed
Committee dossier	CONT/9/03863

Documentation gateway					
Non-legislative basic document		COM(2020)0288	29/06/2020	EC	
Committee draft report		PE657.224	12/01/2021	EP	
Supplementary non-legislative basic document		05793/2021	05/02/2021	CSL	
Committee opinion	LIBE	PE661.917	25/02/2021	EP	
Amendments tabled in committee		PE680.788	04/03/2021	EP	
Committee report tabled for plenary, single reading		A9-0087/2021	30/03/2021	EP	
Text adopted by Parliament, single reading		T9-0177/2021	28/04/2021	EP	Summary

Final act
Budget 2021/1571 OJ L 340 24.09.2021, p. 0211

2019 discharge: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)

The European Parliament decided by 636 votes to 53, with 9 abstentions, to give discharge to the Director of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) for the financial year 2019 and to approve the closure of the accounts for that year.

Noting that the Court of Auditors stated that it had obtained reasonable assurance that the Centre's annual accounts for the financial year 2019 were reliable and that the underlying transactions were legal and regular, Parliament adopted, by 628 votes to 58 with 5 abstentions, a resolution containing a series of recommendations which form an integral part of the discharge decision and which complement the general recommendations contained in the [resolution](#) on the performance, financial management and control of EU agencies.

Centres financial statements

The EMCDDA's final budget for the financial year 2019 was EUR 18 178 352.57, which is an increase of 12.39% compared to 2018. The increase in the budget is mainly due to the launch of the new Instrument for Pre-Accession Assistance 7 (IPA 7).

Budgetary and financial management

Parliament welcomed the budget monitoring efforts made during the 2019 financial year, which resulted in a budget implementation rate of 100%, identical to that recorded in 2018. The implementation rate of payment appropriations was 98.29%, an increase of 0.28% compared to the previous year.

Other observations

Members also made a series of observations concerning performance, staff, procurement, conflict of interest management and internal controls.

In particular, they noted that:

- the 2019 work programme is largely implemented and the Centre has introduced a new performance measurement model in 2019;
- the Centre plays an important role in providing policy makers and practitioners with a range of analysis and information on drugs and drug addiction and trends, with a view to effectively combating drug abuse and trafficking;
- the Centre partially met its objective in terms of training days per staff member, in terms of public service costs and in terms of its contribution

to 14 major scientific and practice drug events;

- on 31 December 2019, 94.74% of the establishment plan was executed with 9 officials and 63 temporary agents appointed out of the 10 officials and 66 temporary agents authorised under the Union's budget;
- the Centre recorded a close gender balance within the Management Board in 2019 (16 men and 14 women) but the geographical balance of staff needs to be improved;
- the issue of dependence on external recruitment needs to be addressed and applicable labour law respected;
- in 85 out of 92 procedures, representing 60% of the total value of the contracts, the Centre attributed direct contracts in procedures with single tenders. Members recommended the use of procedures involving multi candidates, even for low-value contracts;
- the Centre has taken steps to ensure transparency, prevent and manage conflicts of interest and protect whistleblowers; Members called for the creation of a common ethical framework for all EU institutions and agencies;
- the final version of the repository for the new internal control framework was approved by the Centres Director in March 2019 but the anti-fraud strategy should be updated.